ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 166 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2018. The put-call ratio across all filers is 9.02 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $2,324,000 | +108.6% | 16,791 | +23.9% | 0.01% | +75.0% |
| Q3 2020 | $1,114,000 | +20.0% | 13,553 | +14.3% | 0.00% | +33.3% |
| Q2 2020 | $928,000 | +129.1% | 11,858 | +30.2% | 0.00% | +50.0% |
| Q1 2020 | $405,000 | +11.0% | 9,111 | +6.6% | 0.00% | +100.0% |
| Q4 2019 | $365,000 | -10.5% | 8,548 | -10.3% | 0.00% | -50.0% |
| Q3 2019 | $408,000 | -29.7% | 9,530 | +4.4% | 0.00% | 0.0% |
| Q2 2019 | $580,000 | +11.1% | 9,130 | +21.4% | 0.00% | 0.0% |
| Q1 2019 | $522,000 | +119.3% | 7,522 | +37.4% | 0.00% | +100.0% |
| Q4 2018 | $238,000 | -44.3% | 5,473 | -2.2% | 0.00% | -50.0% |
| Q3 2018 | $427,000 | +0.2% | 5,596 | +0.9% | 0.00% | 0.0% |
| Q2 2018 | $426,000 | +64.5% | 5,547 | +9.3% | 0.00% | +100.0% |
| Q1 2018 | $259,000 | +2.0% | 5,075 | -7.2% | 0.00% | 0.0% |
| Q4 2017 | $254,000 | +6.3% | 5,471 | +42.1% | 0.00% | 0.0% |
| Q2 2017 | $239,000 | -0.8% | 3,851 | +8.4% | 0.00% | -50.0% |
| Q1 2017 | $241,000 | – | 3,552 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |